Chitosan-based macrophage-mediated drug targeting for the treatment of experimental visceral leishmaniasis

Journal of Microencapsulation

Volumn 28, Issue 4, 2011, Pages 301-310

  Kunjachan, Sijumon ^a   Gupta, Swati ^a   Dwivedi, Anil K ^a   Dube, Anuradha ^a   Chourasia, Manish K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

chitosan; drug targeting; leishmaniasis; macrophage uptake; microparticles; passive targeting

Indexed keywords

CATION; CHITOSAN; DEXTRAN SULFATE; DOXORUBICIN; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG TARGETING; ENDOCYTOSIS; EVALUATION; EXPERIMENTAL INFECTION; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MACROPHAGE; MALE; NONHUMAN; PARTICLE SIZE; SURFACE PROPERTY; SWELLING; SYRIAN HAMSTER; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CHITOSAN; CRICETINAE; DOXORUBICIN; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; LEISHMANIASIS, VISCERAL; MACROPHAGES; MESOCRICETUS; MICE;

EID: 79955829562     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.559281     Document Type: Article

References (27)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release, 2002;79:29-40. (Pubitemid 34164159)
2. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem, 1982;51:531-54.
3. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother, 1991;28(Suppl B):111-18.
4. Dube A, Gupta R, Singh N. Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol, 2009;25:432-9.
5. Fallon RJ, Schwartz AL. Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Delivery Rev, 1989;4:49-63. (Pubitemid 19264320)
6. Fernandez-Guerroro ML, Aguado JM, Buzcn L, Barros C, Montalban C, Martin T, Bouza E. Visceral leishmaniasis in immunocompromised hosts. Am J Med, 1987;83:1098-102. (Pubitemid 18098884)
7. Gupta S, Dube A, Vyas SP. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target, 2007a;15:437-44. (Pubitemid 47073059)
8. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, Dube A. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics, 2007b;7:816-823. (Pubitemid 46450658)
9. Herwaldt BL. Leishmaniasis. The Lancet, 1999;354:1191-9. (Pubitemid 29460458)
10. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Controlled Release, 2001;73:255-67. (Pubitemid 32539254)
11. Kumar P, Kumar A, Verma SS, Dwivedi N, Singh N, Siddiqi MI, Tripathi RP, Dube A, Singh N. Leishmania donovani pteridine reductase 1: Biochemical properties and structure-modeling studies. Exp Parasitol, 2008;120:73-9.
12. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets, 2008;9:938-47.
13. Kweon HY, Um IC, Park YH. Structural and thermal characteristics of Antheraea pernyi silk fibroin/chitosan blend film. Polymer, 2001;42:6651-6. (Pubitemid 32433461)
14. Leo E, Cameroni R, Forni F. Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm, 1999;180:23-30. (Pubitemid 29131439)
15. Manandhar KD, Yadav TP, Prajapati VK, Kumar S, Rai M, Dube A, Srivastava ON, Sundar S. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother, 2008;62:376-80. (Pubitemid 351984784)
16. Melby PC, Chandrasekar B, Zhao W, Coe JE. The hamsters as a model of human visceral leishmaniasis: Progressive disease and impaired generation of nitric oxide in the face of a prominent Th-1 like cytokine response. J Immunol, 2001;166:1912-20. (Pubitemid 32114678)
17. Misra P, Khaliq T, Dixit A, Sengupta S, Samant M, Kumari S, Kumar A, Kushawaha PK, Majumder HK, Saxena AK, et al. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: An approach for rational drug design. J Antimicrob Chemother, 2008;62:998-1002.
18. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev, 2001;53:283-318. (Pubitemid 32476118)
19. Mukherjee S, Das L, Kole L, Karmakar S, Datta N, Das PK. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis. J Infect Dis, 2004;189:1024-34. (Pubitemid 38373095)
20. Sett R, Basu N, Ghosh AK, Das PK. Potential of doxorubicin as an antileishmanial agent. J Parasitol, 1992;78:350-4.
21. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 2004;274:1-33. (Pubitemid 38457003)
22. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med, 2002;347:1739-46. (Pubitemid 35375612)
23. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health, 2001;6:849-54. (Pubitemid 33010870)
24. Tiyaboonchai W, Limpeanchob N. Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm, 2007;329:142-9. (Pubitemid 44937518)
25. Torchilin VP. Drug targeting. Eur J Pharm Sci, 2000;11(Suppl 2):S81-91. Tripathi KD. 2000. Essentials of medical pharmacology. New Delhi, India: Jaypee Brothers, Medical Publishers Pvt. Ltd.
26. Wang YM, Sato H, Adachi I, Horikoshi I. Optimization of the formulation design of chitosan microspheres containing cisplatin. J Pharm Sci, 1996;85:1204-10. (Pubitemid 26372889)
27. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine, 2007;25(11): 2085-94. (Pubitemid 46227669)